Neurochem Inc - Report of Foreign Issuer (6-K)
12 4월 2008 - 5:27AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: April, 2008
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier
Boulevard
Laval, Québec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F or Form 40 F.
Form 20-F
¨
Form 40-F
þ
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Yes
¨
No
þ
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):
Yes
¨
No
þ
Indicate by check mark whether the registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule 12g-3 under the
Securities Exchange Act of 1934.
Yes
¨
No
þ
If Yes is marked, indicate below the file number assigned to the registrant in connection with
Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
April 11, 2008
|
|
|
|
|
|
By:
|
/s/ David Skinner
|
|
|
|
David Skinner, Vice-President
|
|
|
|
General Counsel and Corporate Secretary
|
|
|
Neurochem Inc
.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7
For further information, please contact:
|
|
|
|
Lise Hébert, PhD
Vice President, Corporate Communications
|
|
Tel: 450-680-4572
lhebert@neurochem.com
|
NEUROCHEM ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
Neurochem will host a live Web conference on Tuesday, April 15, 2008, at 10:00 AM ET
LAVAL, Quebec, April 11, 2008
Dr. Francesco Bellini, Chairman, President and Chief Executive
Officer of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), as well as members of senior management,
cordially invite you to attend the Companys Annual and Special Meeting of shareholders on Tuesday,
April 15, 2008. The meeting will take place at 10:00 A.M. ET, in the Maxwell-Cummings Auditorium
of the Michal and Renata Hornstein Pavilion of the Montreal Museum of Fine Arts, located at 1379
Sherbrooke Street West, Montreal, Quebec.
Following the Companys presentation, attendees will have the opportunity to interact with
management through a question and answer period.
Live Web Cast
Neurochems Annual and Special Meeting will be webcast live at 10:00 A.M. ET, on Tuesday, April 15,
2008. The live Web Cast (audio and visual) will be available on the Companys Web site at
www.neurochem.com
. The telephone numbers to access the audio portion of the meeting only are
514-861-0916 or 1-866-303-7746.
A replay of the Web Cast (audio and visual) will be available three hours following the conclusion
of the presentation, and this until April 22, 2008. The telephone numbers to access the audio
replay are 514-861-2272 or 1-800-408-3053, passcode 3257716#.
Please note that the dial-in numbers and Web Cast will not allow participants to ask questions.
Please dial-in or access Neurochems Web site approximately 15 minutes prior to the beginning of
the presentation.
About Neurochem
Neurochem Inc. is a global health company focused on the research, development and
commercialization of products to provide innovative health solutions to address critical unmet
medical needs.
To Contact Neurochem
For additional information on Neurochem and its programs, please call the North American
toll-free number 1-877-680-4500 or visit the Companys Web site at www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are
independently verifiable at the date hereof, may constitute forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.s
control. Such risks include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory
environment in the jurisdictions in which the Neurochem group does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment due to consolidation,
that actual results may vary once the final and quality-controlled verification of data and
analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc.
Consequently, actual future results may differ materially from the anticipated results expressed in
the forward-looking statements. The reader should not place undue reliance, if any, on any
forward-looking statements included in this news release. These statements speak only as of the
date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise
such statements as a result of any event, circumstances or otherwise, unless required by applicable
legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further
risk factors that might affect the Neurochem group and its business.
Neurochem (NASDAQ:NRMX)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Neurochem (NASDAQ:NRMX)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025